Ideal: A 28-week open-label extension of a 24-week double-blind study of the first transdermal patch in Alzheimer's disease

被引：0
|
作者：
Froelich, L. [1 ]
Barone, P. [2 ]
Foerstl, H. [3 ]
Onofrj, M. [4 ]
Nagel, J.
Ros, J. [5 ]
Tekin, S. [6 ]
Orgogozo, J. [7 ]
机构：
[1] Univ Heidelberg, Cent Inst Mental Hlth, D-6800 Mannheim, Germany
[2] Univ Naples Federico 2, Naples, Italy
[3] Tech Univ Munich, D-8000 Munich, Germany
[4] Gabriele DAnnunzio Univ Fdn, Chieti, Italy
[5] Novartis Pharma AG, Basel, Switzerland
[6] Novartis Pharmaceut Corp, E Hanover, NJ USA
[7] CHU Pellegrin, Bordeaux, France
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2007年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [1] A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease
    Reisberg, B
    Doody, R
    Stöffler, A
    Schmitt, F
    Ferris, S
    Möbius, HJ
    ARCHIVES OF NEUROLOGY, 2006, 63 (01) : 49 - 54
  • [2] Safety and Tolerability of the Rivastigmine Patch Results of a 28-week Open-label Extension
    Grossberg, George
    Sadotvsky, Carl
    Foerstl, Haas
    Froelich, Lutz
    Nagel, Jennifer
    Tekin, Sibel
    Zechner, Stefanie
    Ros, Jacqueline
    Orgogozo, Jean-Marc
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2009, 23 (02): : 158 - 164
  • [3] Dienogest for Treatment of Endometriosis in Women: A 28-Week, Open-Label, Extension Study
    Yu, Qi
    Zhang, Shulan
    Li, Huajun
    Wang, Ping
    Zvolanek, Michal
    Ren, Xiaowei
    Dong, Liying
    Lang, Jinghe
    JOURNAL OF WOMENS HEALTH, 2019, 28 (02) : 170 - 177
  • [4] A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Subbiah, P
    Whalen, E
    NEUROLOGY, 2001, 57 (04) : 613 - 620
  • [5] An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients
    Knopman, D
    Patterson, M
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2001, 15 (03): : 162 - 165
  • [6] Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Idiopathic Inflammatory Myopathy: Results of the 24-Week Double-Blind and 28-Week Open-Label Periods
    Aggarwal, Rohit
    Lundberg, Ingrid
    Song, Yeong-Wook
    Shaibani, Aziz
    Werth, Victoria
    Maldonado, Michael
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4443 - 4446
  • [7] Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease
    Ott, Brian R.
    Blake, Lesley M.
    Kagan, Ethel
    Resnick, Malca
    JOURNAL OF NEUROLOGY, 2007, 254 (03) : 351 - 358
  • [8] Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease
    Brian R. Ott
    Lesley M. Blake
    Ethel Kagan
    Malca Resnick
    Journal of Neurology, 2007, 254 : 351 - 358
  • [9] A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease
    Ruether, E
    Husmann, R
    Kinzler, E
    Diabl, E
    Klingler, D
    Spatt, J
    Ritter, R
    Schmidt, R
    Taneri, Z
    Winterer, W
    Koper, D
    Kasper, S
    Rainer, M
    Moessler, H
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (05) : 253 - 263
  • [10] Safety and efficacy of paliperidone extendedrelease in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
    Zhang, Hongyan
    Li, Huafang
    Liu, Yanning
    Wu, Cathy
    Wu, Qingqi
    Nuamah, Isaac
    Shi, Jianguo
    Xie, Shiping
    Wang, Gang
    Gopal, Srihari
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 : 69 - 77
12345